Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
Lincoln Pharmaceuticals Ltd
Note Receivable
Lincoln Pharmaceuticals Ltd
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Lincoln Pharmaceuticals Ltd
NSE:LINCOLN
|
Note Receivable
₹687.4m
|
CAGR 3-Years
36%
|
CAGR 5-Years
38%
|
CAGR 10-Years
4%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Note Receivable
₹2.3B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Note Receivable
₹3.3B
|
CAGR 3-Years
1 392%
|
CAGR 5-Years
45%
|
CAGR 10-Years
0%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Note Receivable
₹10.9B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-2%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Note Receivable
₹2.3B
|
CAGR 3-Years
87%
|
CAGR 5-Years
18%
|
CAGR 10-Years
7%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Note Receivable
₹1.5B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Lincoln Pharmaceuticals Ltd
Glance View
Lincoln Pharmaceuticals Ltd. is a holding company, which engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The firm offers products, such as tablets, capsules, liquid injection, cream in tubes, dry power injection, liquid in bott, liquid injection and pharma products. The company has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, vitamin-minerals and iron preparations, among others. The firm serves approximately 60 countries in Europe, Latin America, Africa, Asia Pacific, Southeast Asia and 26 States across India. The firm's products include ARHL Tablet (used to treat chloroquine resistant falciparum malaria symptoms), Ibuprofen Tablet (used to treat pain, fever, and inflammation), Dolomol Tablet (used to treat aches and pains), Namcold Tablet (used to treat common cold symptoms) and Tinnex Capsule used to treat tinnitus.
See Also
What is Lincoln Pharmaceuticals Ltd's Note Receivable?
Note Receivable
687.4m
INR
Based on the financial report for Dec 31, 2024, Lincoln Pharmaceuticals Ltd's Note Receivable amounts to 687.4m INR.
What is Lincoln Pharmaceuticals Ltd's Note Receivable growth rate?
Note Receivable CAGR 10Y
4%
Over the last year, the Note Receivable growth was 18%. The average annual Note Receivable growth rates for Lincoln Pharmaceuticals Ltd have been 36% over the past three years , 38% over the past five years , and 4% over the past ten years .
You don't have any saved screeners yet